Halozyme Therapeutics Inc (HALO)
49.00
+3.30
(+7.23%)
USD |
NASDAQ |
Nov 22, 16:00
48.52
-0.48
(-0.99%)
After-Hours: 20:00
Halozyme Therapeutics Research and Development Expense (Quarterly): 18.46M for Sept. 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 18.46M |
| June 30, 2024 | 21.04M |
| March 31, 2024 | 19.11M |
| December 31, 2023 | 21.34M |
| September 30, 2023 | 17.32M |
| June 30, 2023 | 19.73M |
| March 31, 2023 | 17.98M |
| December 31, 2022 | 22.57M |
| September 30, 2022 | 16.70M |
| June 30, 2022 | 15.48M |
| March 31, 2022 | 11.85M |
| December 31, 2021 | 10.11M |
| September 30, 2021 | 8.486M |
| June 30, 2021 | 8.069M |
| March 31, 2021 | 9.009M |
| December 31, 2020 | 7.38M |
| September 30, 2020 | 7.747M |
| June 30, 2020 | 8.951M |
| March 31, 2020 | 10.16M |
| December 31, 2019 | 45.11M |
| September 30, 2019 | 30.46M |
| June 30, 2019 | 33.91M |
| March 31, 2019 | 31.33M |
| December 31, 2018 | 36.65M |
| September 30, 2018 | 35.54M |
| Date | Value |
|---|---|
| June 30, 2018 | 40.09M |
| March 31, 2018 | 37.98M |
| December 31, 2017 | 41.38M |
| September 30, 2017 | 33.99M |
| June 30, 2017 | 38.34M |
| March 31, 2017 | 36.94M |
| December 31, 2016 | 41.35M |
| September 30, 2016 | 33.86M |
| June 30, 2016 | 35.53M |
| March 31, 2016 | 40.10M |
| December 31, 2015 | 27.75M |
| September 30, 2015 | 27.61M |
| June 30, 2015 | 21.20M |
| March 31, 2015 | 16.68M |
| December 31, 2014 | 19.73M |
| September 30, 2014 | 19.90M |
| June 30, 2014 | 18.65M |
| March 31, 2014 | 21.42M |
| December 31, 2013 | 20.93M |
| September 30, 2013 | 25.69M |
| June 30, 2013 | 27.99M |
| March 31, 2013 | 22.03M |
| December 31, 2012 | 18.57M |
| September 30, 2012 | 19.50M |
| June 30, 2012 | 16.08M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
7.38M
Minimum
Dec 2020
45.11M
Maximum
Dec 2019
15.83M
Average
16.09M
Median
Research and Development Expense (Quarterly) Benchmarks
| Lexicon Pharmaceuticals Inc | 25.78M |
| Novavax Inc | 87.16M |
| Kura Oncology Inc | 41.70M |
| TransMedics Group Inc | 14.27M |
| Pulmonx Corp | 3.744M |